MAIN AGENDA

Singapore, 18 - 20 March 2019

Schedule

Create your personal agenda –check the favourite icon

Mar 1908:50
Conference pass
Mar 1909:00
Conference pass

Going global and keeping it local: Is biotech innovation sustainable in Asia?

Keynotes
In this keynote presentation, Sir David Lane, one of the key scientists credited on the discovery of cancer gene p53, a gene which mutation cause near 50% of all human cancer, will share his view on how biomedical sciences have developed in Singapore, Japan and the remaining APAC region, and prospects for Asian biotech and pharma industry.
Mar 1909:20
Conference pass

Looking east: Integrating Asia into the global era of innovative medicine

Keynotes
Mar 1909:40
Conference pass

Pharma Trends: Women health as the next focus

Keynotes
Women’s health goes beyond mother & childcare. For instance, women has a higher risk of cardiovascular diseases compared to men, hence there is a need to invest more on addressing the biological differences in mainstream disease studies to ensure a more effective, personalised treatment. In addition, big data & AI application on female subjects may also differ from male subjects, prompting a need to investigate how studies should be developed differently in the future. This panel brings experts to debate and discuss how femtech is shaping to be the next global pharma focus and the new areas of focus in women's healthcare.
Marcel Van Duin, VP Research, Therapeutic Area Head, Reproductive Medicine & Women's Health, Ferring PharmaceuticalsUnited States
Evelyn Pang, Head Of Operations, Sanofi PasteurSingapore
Mar 1911:15
Conference pass

Chair's opening remarks

Immunotherapy
Mar 1911:15
Conference pass

Chair's opening remarks

Biotech Inve$t
Mar 1911:20
Conference pass
Mar 1911:20
Conference pass

A provider’s perspective in ensuring clinical trial quality

Clinical trials
  • Suggestions in promoting collaboration required between pharma, CRO and providers to promote trial efficiency
  • Educational efforts and processes preparation required to ensure trials quality
  • Case study sharing
Mar 1911:20
Conference pass

Stakeholder mapping, acquisition & activation strategies

Access
Mar 1911:20
Conference pass

The transformation of the Bio pharma industry. Top growth opportunities for 2025

Pharma 4.0
Mar 1911:20
Conference pass

Medtech, Diagnostics, Wearables- What are the next trends in biotech investment landscape?

Biotech Inve$t
Dean Ho, Co-Founder, KYAN TherapeuticsUnited States
Mario Gattino, Chief Executive Officer, RespiriAustralia
Ashish Patel, Head Of Research, Investment Manager, Mercia TechnologiesUnited Kingdom
Mar 1911:40
Conference pass

How do domestic companies gain edge in the competitive global immunotherapy landscape?

Immunotherapy
Mar 1911:40
Conference pass

Personalised risk assessment in clinical management

Clinical trials
  • Disease management and specific screening for better risk assessment
  • Targeted screening and clinical management of specific disease profile
  • Product strategy and clinical development plan in establishing oncology pipelines
Mar 1911:40
Conference pass

The role of industry in facilitating low to mid income countries to build capabilities and healthcare accessibility

Access
Mar 1911:40
Conference pass

Increasing transparency and knowledge-sharing efficiency with blockchain

Pharma 4.0
Mar 1912:00
Conference pass

The next big trend in Asia immunotherapy landscape: A case study in China

Immunotherapy
Mar 1912:00
Conference pass

New considerations in ensuring trials efficiency and transparency

Clinical trials
This presentation shares insights from Asia, EMA and FDA inspections with case studies on biosimilar trials. It will also discuss the influence of the nature of company on site monitoring activities
Hyejin Shin, Director, Group Leader, Clinical Qa, Samsung BioepisRepublic Of Korea
Mar 1912:00
Conference pass

Collaborative efforts in building the common ground for better accessibility and treatment

Access
  • Key actions to bridge the gaps between stakeholders to provide for population in need
  • Models in helping advocacy group to coordinate for better access to treatment
  • Building the common ground in promoting better collaboration between advocacy groups, government, pharma and other stakeholders
Nadia Suttikulpanich, Head Of Fuchsia Innovation Center For Muang Thai Life Assurance, Muang Thai Life Assurance Public CompanyThailand
Mar 1912:00
Conference pass

AI- enhanced drug development platforms

Pharma 4.0
Mar 1912:00
Conference pass

Biotech Pitch

Biotech Inve$t
10 minutes per company
Jeong Beom Kim, Associate Professor, SuPine TherapeuticsRepublic Of Korea
Ken Taylor, Chief Executive Officer, Living Cell Technologies LimitedAustralia
Poh Loong Soong, Co-Founder, Ternion Biosciences Pte. LtdSingapore
Younggyu Cho, Chief Technology Officer, Y BiologicsRepublic Of Korea
Mar 1912:20
Conference pass

Development of cell therapy product for pediatric orphan disease - challenges and rewards

Immunotherapy
  • Case study on current and upcoming immunotherapy and stem cell products, i.e. Cartistem, Pneumostem (orphan indication for premature babies)
  • Discussion on strategies in making immunotherapy and stem cell products more accessible for population in Asia, future plans and what’s next beyond Asia?
Mar 1912:20
Conference pass

Overview of regulatory authority inspections in EU, US, JP and CN (GCP, GVP)

Clinical trials
Contact Jon at jonathan.mottram@terrapinn.com or +65 6322 2738 to speak at this session.
Mar 1912:20
Conference pass

Innovative strategies to cope with the rise of superbugs

Pharma 4.0
Contact Jon at jonathan.mottram@terrapinn.com or +65 6322 2738 to speak at this session.
T Balganesh, President, GangaGenIndia
Mar 1912:40
Conference pass

R&D Management: Additional value enhancement through innovation

Pharma 4.0
Raphael Aswin Susilo, Vice President - Research And Development, Regulatory And Medical Affairs, Soho Global HealthIndonesia
Mar 1914:10
Conference pass
Mar 1914:10
Conference pass
Mar 1914:20
Conference pass

Big pharma perspectives: Using global pipeline development to serve Asia’s population

Immunotherapy
Mar 1914:20
Conference pass

Clinical research as tools in driving innovation

Clinical trials
Mar 1914:20
Conference pass

Maximizing RWE and PRO in Regulatory & reimbursement processes

Access
Mar 1914:20
Conference pass

Building an in-house pharma AI product team: Key steps & considerations

Pharma 4.0
  • In-house vs outsource: What are the key benefits & challenges in building in-house data science projects
  • Ethics in consideration: How to make AI products more neutral and non-discriminative
  • Why data science project fails and how do we prevent it?
Mar 1914:40
Conference pass

Innovative therapeutics in immuno-oncology and inflammatory diseases

Immunotherapy
Mar 1914:40
Conference pass

Improving clinical trials with better stakeholder management

Clinical trials
Mar 1914:40
Conference pass

Making a value-outcome-based reimbursement model possible: How do we get there?

Access
Jun Feng, Market Access Associate Director - Oncology, Japac, AbbvieSingapore
Mar 1914:40
Conference pass

Renovating the R&D ecosystem for innovative health science in Japan

Pharma 4.0
Toru Seo, APAC Head, S&E, Worldwide Business Development, Chief Business Officer, PfizerJapan
Mar 1914:45
Conference pass

Biotech Pitch

Biotech Inve$t
10 minutes per company
Woo Shin Jang, Senior Principal Scientist, Yuhan R&D InstituteRepublic Of Korea
Jeff Dao, Operating Officer and Business Development Officer, HighTide TherapeuticsUnited States
Amit Kumar, Co-Founder & CEO, Biopsin Pte LtdSingapore
Mar 1915:00
Conference pass

Glenmark Pharmaceuticals Product Launch

Immunotherapy
Mahboob Rahman, President & Chief Medical Officier, Glenmark Pharmaceuticals LtdUnited States of America
Mar 1915:00
Conference pass
Mar 1915:00
Conference pass

RWE as the basis of value-based reimbursement: Applications in APAC’s pharma industry

Access
  • Overview of data-driven reimbursement process in APAC
  • Overcoming barriers to increase use of real world data
  • Improving quality of real world data
  • Standardising access and quality of RWE analytics
  • Working with payors and regulators on possible value based reimbursement model for innovative drugs and beyond
Jun Feng, Market Access Associate Director - Oncology, Japac, AbbvieSingapore
Bechara Saab, Chief Executive Officer and Chief Scientist, Mobio InteractiveChina
Mar 1915:00
Conference pass

Reshaping your supply chain to address supply shortage: A patient-centric approach

Pharma 4.0
Mar 1915:20
Conference pass

Immunotherapy in clinical practices: Opportunities and key challenges (Topic to be confirmed)

Immunotherapy
Mar 1915:20
Conference pass

Paediatric subject recruitment: A cross industry case study & future trend

Clinical trials
Mar 1916:20
Conference pass

Leveraging larger capital pools: Let’s talk listings & capital markets

Biotech Inve$t
  • Global capital markets and opportunities
  • Biotech market readiness in APAC public listing
  • Hong Kong- the next Asia biotech capital destination?
Atsushi Usami, Partner, The University of Tokyo Edge Capital Co., Ltd.Japan
Billy Cho, Chief Financial Officer, Zai LaboratoryChina
Abraham Cinta, Chief Executive Officer, ARC CapitalSingapore
Mar 1916:40
Conference pass

Beyond prevention: Latest cancer vaccine developments in Asia

Immunotherapy
Mar 1916:40
Conference pass

Leveraging digital platforms and Electronic Medical Record (EMR) to improve patient experience and clinical trials subject recruitment

Clinical trials
Mar 1916:40
Conference pass

Providing affordable access to patients in developing countries and underserved communities

Access
Mar 1916:40
Conference pass

PANEL: Igniting and fostering innovative solutions through collaboration

Pharma 4.0
Hosted by J&J Innovation
Mar 1917:00
Conference pass

Gastric and breast cancer vaccines: Case study and latest findings

Immunotherapy
Mar 1917:00
Conference pass

Innovating clinical trials with digital platforms: A cross industry case study

Clinical trials
Mar 1917:00
Conference pass

Cost management & innovative pricing strategies in high value disease management (topic to be confirmed)

Access
Mar 1917:10
Conference pass

Biotech Pitch

Biotech Inve$t
10 minutes per company
Dong-Hun Woo, COO/CTO, NexelRepublic Of Korea
Nir Arbel, Co-Founder And Chief Executive Officer, CarmentixSingapore
Billy Cho, Chief Financial Officer, Zai LaboratoryChina
Meng Chi Chen, Director Business Development, BRIM BiotechnologyTaiwan
Yi-Chun Maria Chen, Director Of Business Development, Immunwork Inc.Taiwan
Mar 1917:20
Conference pass

Technology transfer and Product Development Partnerships (PDPs) in making vaccines affordable

Access
Dr Sushant Sahastrabuddhe, Director, Enteric Fever, International Vaccine InstituteRepublic Of Korea
Mar 1917:20
Conference pass

Scaling new heights: Fast-tracking success in Asia with open innovation and new partnership opportunities

Pharma 4.0
Mar 1917:40
Conference pass

Breaking the boundary of traditional B2B partnership: Next generation pharma-PE/VC model

Pharma 4.0

Create your personal agenda –check the favourite icon

Mar 2009:00
Conference pass

Disrupt before being disrupted: Using digital tech to connect to previously uneconomic chronic disease customers

Keynotes
Insurance is a tricky part of healthcare business. Increased healthcare costs lead to a higher profit for pharma and provider companies but burdens the government budget and hurts the insurance business. Since taking care of a chronic patient is a lifelong commitment, the availability of insurance to cover this essential treatment is often expensive and uneconomical. Join Nadia Suttikulpanich, Head of the Fuchsia Innovation Center, part of Muang Thai Life Assurance, Thailand as she shares how they are adopting digital tech to pilot chronic disease cover to provide for patients in need while keeping their insurance business profitable.
Nadia Suttikulpanich, Head Of Fuchsia Innovation Center For Muang Thai Life Assurance, Muang Thai Life Assurance Public CompanyThailand
Mar 2009:20
Conference pass

The path to personalised medicine: Key developments

Keynotes
Everyone knows the potential benefits of personalised medicine, but how do we get there? Finding and better defining disease through biomarkers and more accurate diagnostics. Targeted therapeutics to leverage new and emerging diagnostic capabilities. Personalized Medicine to Real-Time Medicine. How to drive success across industry and clinical implementation in an economic manner. This presentation discusses various strategies and key considerations to drive the symbiosis between academia, industry and clinical medicine to drive vastly improved patient outcomes.
Mar 2009:40
Conference pass

Pharma 4:0 Digital disruption: New players, new opportunities

Keynotes
Matt Cooper, Business Development And Research Director, NIHR Clinical Research NetworkUnited Kingdom
Andreas Koester, Vice President Of Clinical Trial Innovation And External Alliances, Johnson & JohnsonUnited States
Mar 2010:20
Conference pass

Attracting VC capital: What are investors looking for from early stage Asian biotechs?

Biotech Inve$t
Moderator: Mayank Gurnani, Associate Professor, Industry Liaison Office, National University of SingaporeSingapore
Hsien-Hui Tong, Head, Venture Investing, SGInnovateSingapore
Mar 2010:21
Conference pass

Table 1 Working with clinical outsourcing partners: Risk management and prevention

Keynotes
Mar 2010:21
Conference pass

Table 2 Fostering commercial partnerships to tap on emerging APAC markets

Keynotes
Mar 2010:21
Conference pass

Table 3 Regulatory collaboration and opportunities in more efficient drug development

Keynotes
Mar 2010:21
Conference pass

Table 4 Strategies in making drugs more affordable and accessible to patients in developing countries

Keynotes
Mar 2010:21
Conference pass

Table 5 Universal healthcare- Is it really costly?

Keynotes
Mar 2010:21
Conference pass

Table 6 A convergent approach: Tapping on western expertise to serve Asia population

Keynotes
Mar 2010:21
Conference pass

Table 7 Precision to personalised medicine- How do we get there?

Keynotes
Mar 2010:21
Conference pass

Table 8 Leveraging blockchain technology in making clinical trials more transparent and efficient

Keynotes
Mar 2010:21
Conference pass

Table 9: Data Science in practice: How can sales reps and MSLs use Big Data?

Keynotes
Mar 2010:22
Conference pass

Table 10: The Singapore biotech ecosystem – What comes after the Inflexion?

Keynotes
Mar 2011:00
Conference pass

Funding risk & return strategies: Investor & investee perspectives

Biotech Inve$t
Anthony Desir, Director, MoexaHong Kong
Mar 2011:40
Conference pass

Overview: Targeted therapies in enabling precision medicine

Immunotherapy
  • Combination studies in Asia-latest updates
  • Deciding between targeted oncology therapies vs I-O, key considerations
  • Key actions transitioning from followers to leaders in targeted therapies
Mar 2011:40
Conference pass
Mar 2011:40
Conference pass

Convergence, harmonisation and collaboration: The evolution of Asia’s pharma regulatory landscape

Regulatory Affairs
Mar 2011:40
Conference pass

Beyond the pill, beyond the scalpel: New approaches to medicine in the realm of the digital and electronic

Pharma 4.0
Mar 2012:00
Conference pass

Clinical Development of CAR-T, Stem Cells and other Cellular Therapy Products

Clinical trials
Mar 2012:00
Conference pass

Challenges, opportunities and partnerships in the ASEAN pharma industry: A regulatory perspective

Regulatory Affairs
Kum Cheun Wong, Head Asia Pacific Policy And Liaison, Drug Regulatory Affairs, Novartis Asia PacificSingapore
Mar 2012:00
Conference pass

Innovating with the patient for the patient: Using data for patient engagement in clinical trials

Pharma 4.0
Andreas Koester, Vice President Of Clinical Trial Innovation And External Alliances, Johnson & JohnsonUnited States
Mar 2012:20
Conference pass

Development of next generation tumor immunotherapy

Immunotherapy
Mar 2012:20
Conference pass

Gearing up for a clinic with CRISPR technology: New strategies

Clinical trials
Mar 2012:20
Conference pass

Digital intervention in streamlining regulatory publishing & submission activities

Regulatory Affairs
Handsome Ji, Apac Publishing Lead, Pfizer ChinaChina
Mar 2012:40
Conference pass

Next generation targeted agents and immuno-oncology therapies

Immunotherapy
Mar 2012:40
Conference pass

Transitioning from an US food to an Asian drug company: A case study in clinical development

Clinical trials
Judith Walker, Chief Medical Officer, CerecinSingapore
Mar 2012:40
Conference pass

Stakeholder management in regulatory affairs: A case study

Regulatory Affairs
Mar 2012:40
Conference pass

Harnessing clinically validated AI to optimise drug development and digital medicine

Pharma 4.0
Dean Ho, Co-Founder, KYAN TherapeuticsUnited States
Mar 2013:00
Conference pass
Mar 2013:50
Conference pass

Biotech Pitch

Biotech Inve$t
10 minutes per company
Hoon Seong, Deputy manager, Genome & CompanyRepublic Of Korea
Alexander Kort, Senior Vice President Corporate Development, Themis Bioscience GmbHAustria
Wei Jiang Goh, Co-Founder & CEO, Craft HealthSingapore
Ignacio Asial, Founder & CEO, DOTBIOSingapore
Mar 2014:30
Conference pass

When two readily becomes one: Opportunities in bispecific antibodies

Immunotherapy
Mar 2014:30
Conference pass

Clinical trial capacity related to MRCT in Taiwan

Clinical trials
Mar 2014:30
Conference pass
Mar 2014:50
Conference pass

Next generation combination therapies with bioconjugation

Immunotherapy
Gang Qin, Chief Executive Officer, GeneQuantum Healthcare SuzhouChina
Mar 2014:50
Conference pass

GCP and safety guidelines for biosimilars products

Clinical trials
Mar 2014:50
Conference pass

Expedited review pathways in North East Asia and what it means for APAC stakeholders

Regulatory Affairs
  • Priority review and reform for new product launches in China
  • Latest updates on Good registration management (GRM) and approval pathways in Japan, Korea, Taiwan
  • Opportunities to expand to greater Asia and lessons for the rest of Asia
Handsome Ji, Apac Publishing Lead, Pfizer ChinaChina
Finny Liu, Apac Regional Regulatory Policy Lead, RocheSingapore
Mar 2014:50
Conference pass

Remote patient management solutions for better engagement

Pharma 4.0
Mar 2015:10
Conference pass

Reserved for sponsor

Clinical trials
Contact Jon at jonathan.mottram@terrapinn.com or +65 6322 2738 to speak at this session.
Mar 2015:10
Conference pass

Virtual Reality for patient care and engagement

Pharma 4.0
Mar 2015:30
Conference pass
Mar 2015:30
Conference pass

MRCT in Asia: Implications & opportunities

Clinical trials
  • Accounting regional differences in stepwise expansions
  • Selection of suitable geographical regions
  • How do South East Asia companies tap on MRCT opportunities in their near future strategies
Mar 2015:30
Conference pass

The role of pharmacovigilance in ensuring health product safety

Regulatory Affairs
Mar 2015:30
Conference pass

Complement or replacement? Envisioning the future of digital therapeutics

Pharma 4.0
Mar 2015:30
Conference pass
Mar 2015:50
Conference pass

Quality Management System of CAR-T cell therapy

Regulatory Affairs
Mar 2015:50
Conference pass

Using real world data in digital intervention

Pharma 4.0
Teng Yan Yau, Chief Medical Officer, HolmuskSingapore
Mar 2016:10
Conference pass

Applying precision and immunotherapy to prevent infectious diseases

Immunotherapy
Alexander Kort, Senior Vice President Corporate Development, Themis Bioscience GmbHAustria
Mar 2016:10
Conference pass

Regulatory compliance in biologic products comparability following technology transfer

Regulatory Affairs
Mar 2016:10
Conference pass

Choosing the right business model for digital therapeutics

Pharma 4.0
Bechara Saab, Chief Executive Officer and Chief Scientist, Mobio InteractiveChina
last published: 19/Feb/19 03:35 GMT

 

 

DOWNLOAD PROSPECTUS

 

 

For speaking, sponsorship and exhibition opportunities contact jonathan.mottram@terrapinn.com
Tel: +65 6322 2738